◎ Sugi Atlas

Atlas / Gene / DDO

DDO

gene
On this page

Also known as DASOXDASPO

Summary

DDO (D-aspartate oxidase, HGNC:2727) is a protein-coding gene on chromosome 6q21, encoding D-aspartate oxidase (Q99489). Selectively catalyzes the oxidative deamination of acidic amino acids.

The protein encoded by this gene is a peroxisomal flavoprotein that catalyzes the oxidative deamination of D-aspartate and N-methyl D-aspartate. Flavin adenine dinucleotide or 6-hydroxyflavin adenine dinucleotide can serve as the cofactor in this reaction. Several transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 8528 — RefSeq curated summary.

At a glance

  • GWAS associations: 20
  • Clinical variants (ClinVar): 77 total
  • Druggable target: yes
  • MANE Select transcript: NM_001372108

Identifiers

Gene identifiers

FieldValue
HGNC IDHGNC:2727
Approved symbolDDO
NameD-aspartate oxidase
Location6q21
Locus typegene with protein product
StatusApproved
AliasesDASOX, DASPO
Ensembl geneENSG00000203797
Ensembl biotypeprotein_coding
OMIM124450
Entrez8528

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 10 protein_coding, 1 nonsense_mediated_decay

ENST00000368923, ENST00000368924, ENST00000479373, ENST00000854438, ENST00000854439, ENST00000854440, ENST00000854441, ENST00000951844, ENST00000951845, ENST00000951846, ENST00000951847

RefSeq mRNA: 7 — MANE Select: NM_001372108 NM_001368170, NM_001368172, NM_001368173, NM_001368174, NM_001368175, NM_001372108, NM_004032

CCDS: CCDS5082, CCDS5083

Canonical transcript exons

ENST00000368924 — 5 exons

ExonStartEnd
ENSE00000839913110408334110408442
ENSE00003541060110404774110404950
ENSE00003844124110415467110415575
ENSE00003845411110391784110393342
ENSE00003898558110413291110413466

Expression profiles

Bgee: expression breadth ubiquitous, 205 present calls, max score 85.09.

FANTOM5 (CAGE): breadth broad, TPM avg 1.5820 / max 108.5483, expressed in 618 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter IDTPM avgSamples expressed
750471.5820618

Top tissues by expression

276 total, by Bgee expression score (0-100, higher = more expressed):

TissueAnatomy IDExpression scoreQuality
heart left ventricleUBERON:000208485.09gold quality
cardiac ventricleUBERON:000208284.72gold quality
apex of heartUBERON:000209884.60gold quality
heart right ventricleUBERON:000208082.03gold quality
myocardiumUBERON:000234980.88silver quality
left ventricle myocardiumUBERON:000656680.79gold quality
heartUBERON:000094880.62gold quality
right adrenal glandUBERON:000123380.29gold quality
right adrenal gland cortexUBERON:003582779.90gold quality
right atrium auricular regionUBERON:000663179.89gold quality
left adrenal glandUBERON:000123479.73gold quality
nephron tubuleUBERON:000123179.37gold quality
hindlimb stylopod muscleUBERON:000425279.32gold quality
cardiac atriumUBERON:000208179.24gold quality
left adrenal gland cortexUBERON:003582578.89gold quality
right lobe of liverUBERON:000111478.17gold quality
putamenUBERON:000187477.80gold quality
liverUBERON:000210777.44gold quality
adrenal cortexUBERON:000123577.34gold quality
caudate nucleusUBERON:000187377.34gold quality
endothelial cellCL:000011576.97silver quality
muscle of legUBERON:000138376.91gold quality
adrenal glandUBERON:000236976.73gold quality
gastrocnemiusUBERON:000138876.43gold quality
cardiac muscle of right atriumUBERON:000337976.23silver quality
nucleus accumbensUBERON:000188276.20gold quality
duodenumUBERON:000211475.48gold quality
C1 segment of cervical spinal cordUBERON:000646975.14gold quality
muscle organUBERON:000163074.85gold quality
kidney epitheliumUBERON:000481974.75gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

ExperimentMarker?Max mean expression
E-ANND-3no3.52

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 11)

  • data do not suggest that DDO plays a role in the etiology of schizophrenia in the German population (PMID:19125110)
  • There is a significant increase in DDO mRNA expression in the prefrontal cortex of patients with schizophrenia compared to controls. (PMID:25689573)
  • Characterization of the enzymatic and structural properties of human D-aspartate oxidase and comparison with those of the rat and mouse enzymes (PMID:25747990)
  • This study is the first to report robust age associations for DNA methylation in MYOF and DDO, both of which have plausible functional roles in aging (PMID:28255110)
  • SNPSs R216Q and S308N reduce enzyme activity towards acidic d-amino acids, decrease the binding affinity for the coenzyme flavin adenine dinucleotide and decrease the temperature stability. Expression of DDO genes carrying the R216Q or S308N SNP substitutions may increase the d-aspartate content in humans and alter homeostasis of several other amino acids. (PMID:28629864)
  • The strongest DNA methylation changes in atopic asthma were detected in the promoter region of SMAD3 gene at chr 15q22.33 and introns of DDO/METTL24 genes at 6q21. (PMID:29729188)
  • three-dimensional structural analysis contributes insights into the structure-function relationships of human DASPO (PMID:31914658)
  • Cellular studies of the two main isoforms of human d-aspartate oxidase. (PMID:33650155)
  • Genetic variants in DDO and PEX5L in peroxisome-related pathways predict non-small cell lung cancer survival. (PMID:35502931)
  • D-aspartate oxidase gene duplication induces social recognition memory deficit in mice and intellectual disabilities in humans. (PMID:35915065)
  • On the regulation of human D-aspartate oxidase. (PMID:37805834)

Cross-species orthologs

9 orthologs

OrganismSymbolGene ID
danio_rerioddoENSDARG00000079664
mus_musculusDdoENSMUSG00000063428
rattus_norvegicusDdoENSRNOG00000000582
drosophila_melanogasterDaao2FBGN0031860
drosophila_melanogasterDaao1FBGN0033543
caenorhabditis_elegansWBGENE00008127
caenorhabditis_elegansWBGENE00017565
caenorhabditis_elegansWBGENE00017648
caenorhabditis_elegansWBGENE00022076

Paralogs (1): DAO (ENSG00000110887)

Protein

Protein identifiers

D-aspartate oxidase — Q99489 (reviewed: Q99489)

All UniProt accessions (3): C9K4X7, F2Z2E0, Q99489

UniProt curated annotations — full annotation on UniProt →

Function. Selectively catalyzes the oxidative deamination of acidic amino acids. Suppresses the level of D-aspartate in the brain, an amino acid that can act as an agonist for glutamate receptors. Protects the organism from the toxicity of D-amino acids. May also function in the intestine.

Subunit / interactions. Monomer. Interacts with PEX5; the interaction is direct and required for localization of DDO to the peroxisome. Interacts with DAOA; the interaction is direct and increases the degradation rate of DDO.

Subcellular location. Peroxisome matrix. Cytoplasm. Cytosol Peroxisome matrix Peroxisome matrix.

Tissue specificity. Expressed in epithelial cells of the proximal nephron tubules in the renal cortex (at protein level). In the brain, expressed in the frontal, temporal, and occipital lobes of the cortex, hippocampus, striatum, diencephalon, brainstem, cerebellum, spinal cord, plexus choroiderus and ependyma (at protein level). Expression is increased in the prefrontal cortex of schizophrenic patients. Levels are normal in the superior frontal gyrus of patients with Alzheimer’s disease.

Post-translational modifications. May be S-nitrosylated.

Activity regulation. Inhibited by the benzodiazepine olanzapine. Inhibited by aminooxyacetic acid, thiolactomycin, malonate and meso-tartrate. Clozapine, haloperidol and chlorpromazine have no effect on activity. Not inhibited by sodium, potassium, magnesium, iron, calcium, cobalt, copper, nickel, manganese or zinc ions. Not inhibited by AMP, ADP, ATP, or cAMP. Not inhibited by pyridoxal 5’-phosphate.

Miscellaneous. Found in the hippocampus of female patients affected by Alzheimer’s disease.

Similarity. Belongs to the DAMOX/DASOX family.

Isoforms (4)

UniProt IDNamesCanonical?
Q99489-1DDO-1, A, DASPO_341yes
Q99489-2DDO-2, DASPO_282
Q99489-33, DASPO_369
Q99489-44

RefSeq proteins (7): NP_001355099, NP_001355101, NP_001355102, NP_001355103, NP_001355104, NP_001359037, NP_004023 (=MANE)

Domains & families (InterPro)

IDNameType
IPR006076FAD-dep_OxRdtaseDomain
IPR006181D-amino_acid_oxidase_CSConserved_site
IPR023209DAOFamily

Pfam: PF01266

Enzyme classification (BRENDA):

  • EC 1.4.3.1 — D-aspartate oxidase (BRENDA: 41 organisms, 94 substrates, 96 inhibitors, 147 Km, 70 kcat entries)

Substrate kinetics (BRENDA)

27 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

SubstrateKm (mM)Measurements
D-ASPARTATE0.38–8.7729
N-METHYL-D-ASPARTATE0.2–10320
D-GLUTAMATE0.23–16618
D-ASP1–13.416
D-GLU0.68–1069
N-METHYL-D-ASP2.85–27.98
D-ASPARAGINE0.38–2407
O20.17–2.016
D-GLUTAMINE25.7–8154
D-PROLINE0.9–4404
D-ASPARTATE DIMETHYLESTER150–5402
D-GLN21–39.42
D-HISTIDINE8.8–962
D-MET8.5–31.82
D-PHE14.3–34.82

Catalyzed reactions (Rhea), 2 shown:

  • D-glutamate + O2 + H2O = 2-oxoglutarate + H2O2 + NH4(+) (RHEA:10028)
  • D-aspartate + O2 + H2O = oxaloacetate + H2O2 + NH4(+) (RHEA:12512)

UniProt features (52 total): strand 16, helix 12, binding site 8, sequence variant 6, turn 3, splice variant 2, sequence conflict 2, chain 1, short sequence motif 1, mutagenesis site 1

Structure

Experimental structures (PDB)

1 structures.

PDBMethodResolution (Å)
6RKFX-RAY DIFFRACTION3.22

Predicted structure (AlphaFold)

ModelpLDDTFraction very-high
AF-Q99489-F196.360.97

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (8): 36; 37; 43; 44; 50; 307; 311; 312

Mutagenesis-validated functional residues (1):

PositionPhenotype
141–143slightly decreases activity.

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

IDPathway
R-HSA-389661Glyoxylate metabolism and glycine degradation
R-HSA-9033241Peroxisomal protein import

MSigDB gene sets: 106 (showing top): GOBP_BEHAVIOR, GOBP_ALPHA_AMINO_ACID_METABOLIC_PROCESS, GOBP_REGULATION_OF_HORMONE_LEVELS, GOBP_INSEMINATION, GOBP_DICARBOXYLIC_ACID_METABOLIC_PROCESS, LINDGREN_BLADDER_CANCER_CLUSTER_2A_UP, GOBP_ORGANIC_ACID_CATABOLIC_PROCESS, GOBP_REPRODUCTIVE_BEHAVIOR, GOBP_ORGANIC_ACID_METABOLIC_PROCESS, GOBP_MULTI_MULTICELLULAR_ORGANISM_PROCESS, GOBP_SMALL_MOLECULE_CATABOLIC_PROCESS, MORF_BMPR2, GOBP_GROOMING_BEHAVIOR, MULLIGHAN_NPM1_SIGNATURE_3_DN, GOBP_AMINO_ACID_CATABOLIC_PROCESS

GO Biological Process (11): aspartate metabolic process (GO:0006531), L-aspartate catabolic process (GO:0006533), insemination (GO:0007320), grooming behavior (GO:0007625), regulation of cell communication (GO:0010646), D-amino acid catabolic process (GO:0019478), hormone metabolic process (GO:0042445), nervous system process (GO:0050877), L-amino acid catabolic process (GO:0170035), proteinogenic amino acid catabolic process (GO:0170040), D-amino acid metabolic process (GO:0046416)

GO Molecular Function (6): D-aspartate oxidase activity (GO:0008445), D-glutamate oxidase activity (GO:0047821), FAD binding (GO:0071949), D-amino-acid oxidase activity (GO:0003884), protein binding (GO:0005515), oxidoreductase activity (GO:0016491)

GO Cellular Component (4): cytoplasm (GO:0005737), peroxisome (GO:0005777), peroxisomal matrix (GO:0005782), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-2 pathways:

CategoryPathways
Metabolism of amino acids and derivatives1
Protein localization1

GO top-level categories

Rollup of top GO terms by namespace:

CategoryTerms
amino acid catabolic process2
carboxylic acid catabolic process2
D-amino-acid oxidase activity2
cellular anatomical structure2
amino acid metabolic process1
dicarboxylic acid metabolic process1
aspartate metabolic process1
dicarboxylic acid catabolic process1
L-amino acid catabolic process1
proteinogenic amino acid catabolic process1
copulation1
multi-organism reproductive process1
multi-multicellular organism process1
multicellular organismal reproductive process1
behavior1
cell communication1
regulation of cellular process1
D-amino acid metabolic process1
non-proteinogenic amino acid catabolic process1
metabolic process1
regulation of hormone levels1
system process1
L-amino acid metabolic process1
proteinogenic amino acid metabolic process1
non-proteinogenic amino acid metabolic process1
flavin adenine dinucleotide binding1
primary methylamine oxidase activity1
binding1
catalytic activity1
intracellular anatomical structure1
microbody1
peroxisome1
microbody lumen1
cytoplasm1

Protein interactions and networks

STRING

1475 interactions, top by confidence (×1000):

Protein AProtein BPartner UniProtScore
DDOSRRQ9GZT4642
DDOPIPOXQ9P0Z9575
DDOPAOXQ6QHF9496
DDOGOT1L1Q8NHS2475
DDOAGXTP21549469
DDOTMEM209Q96SK2442
DDOMETTL24Q5JXM2433
DDOHAO1Q9UJM8429
DDOTYSND1Q2T9J0392
DDOSTRCQ7RTU9382
DDOHAO2Q9NYQ3374
DDONOXRED1Q6NXP6366
DDOLYRM7Q5U5X0353
DDOPUM3Q15397352
DDOLONP2Q86WA8350

IntAct

3 interactions, top by confidence:

ABTypeScore
CFTRCNOT1psi-mi:“MI:0914”(association)0.480
COPS5DDOpsi-mi:“MI:0915”(physical association)0.370

BioGRID (4): DDO (Synthetic Lethality), PEX5 (Reconstituted Complex), DDO (Protein-peptide), DDO (Two-hybrid)

ESM2 similar proteins: A0A6N3IN21, A3KCL7, A4IFH5, A7MBC0, A7MBI7, D3ZDK7, D3ZDM7, E1BNQ4, P09367, P10950, P11172, P13439, P17256, P20132, P24298, P25409, P31754, P46597, P50053, P97328, Q02974, Q03426, Q0VCW4, Q1JPD3, Q3B8E3, Q3TY86, Q3ZKN0, Q5BJJ5, Q5E9T8, Q5M7T9, Q5R514, Q5R824, Q5RD71, Q5RFE6, Q6PCB7, Q6SKR2, Q80W22, Q8CHP8, Q8CIM3, Q8HZJ0

Diamond homologs: A0A095C6S0, A0A095CCB2, A0A499UB99, A3KCL7, C0HMB1, C4R4G9, D3ZDM7, J9VPE7, J9VRT1, P24552, P31228, P80324, Q1AYM8, Q556W1, Q75WF1, Q922Z0, Q99042, Q99489, Q9HGY3, Q9X7P6, Q9Y7N4, A0A7E6FSU6, A2V9Y8, A8WXM1, A8XJ44, O01739, O35078, O45307, P00371, P14920, P18894, P22942, Q19564, Q95XG9, Q9Z1M5, Q9Z302, T2HG31, A5U3S4, P9WP26, P9WP27

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

77 variants total. Per-class counts are floors (≥ shown; pagination cap):

ClassificationCount (floor)
Pathogenic0
Likely pathogenic0
Uncertain significance69
Likely benign4
Benign0

Top pathogenic / likely-pathogenic (0)

SpliceAI

870 predictions. Top by Δscore:

VariantEffectΔscore
6:110414277:AGTCT:Adonor_gain1.0000
6:110408332:AC:Adonor_gain0.9900
6:110408333:CC:Cdonor_gain0.9900
6:110410592:A:Tacceptor_gain0.9900
6:110393341:TCCTA:Tacceptor_loss0.9800
6:110393343:C:CCacceptor_gain0.9800
6:110393343:C:Tacceptor_loss0.9800
6:110393344:T:Aacceptor_loss0.9800
6:110408450:C:CTacceptor_gain0.9800
6:110408462:CAAAG:Cacceptor_gain0.9800
6:110413467:C:CCacceptor_gain0.9700
6:110408328:ACTT:Adonor_loss0.9600
6:110408329:CTTA:Cdonor_loss0.9600
6:110408330:TTA:Tdonor_loss0.9600
6:110408331:TA:Tdonor_loss0.9600
6:110408332:A:ATdonor_loss0.9600
6:110408333:C:Gdonor_loss0.9600
6:110408443:C:CCacceptor_gain0.9600
6:110410584:A:Cacceptor_gain0.9600
6:110415462:AGTAC:Adonor_loss0.9600
6:110415463:GTACC:Gdonor_loss0.9600
6:110415464:TACCT:Tdonor_loss0.9600
6:110415465:A:Cdonor_loss0.9600
6:110415466:C:Tdonor_loss0.9600
6:110408327:CACT:Cdonor_loss0.9500
6:110413285:TCTCA:Tdonor_loss0.9500
6:110413286:CTCA:Cdonor_loss0.9500
6:110413287:TCA:Tdonor_loss0.9500
6:110413288:CAC:Cdonor_loss0.9500
6:110413289:ACC:Adonor_loss0.9500

AlphaMissense

2389 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000136346 (6:110396131 G>A,T), RS1000200224 (6:110416795 G>T), RS1000321543 (6:110390570 G>A,C), RS1000340903 (6:110406104 A>G), RS1000364417 (6:110402359 A>C), RS1000398020 (6:110416674 G>A), RS1000441523 (6:110390204 G>A), RS1000635176 (6:110412640 C>T), RS1000900690 (6:110401101 G>A), RS1000986379 (6:110400602 A>G), RS1001034900 (6:110411465 T>C), RS1001048704 (6:110389640 C>A), RS1001058210 (6:110388713 G>A,T), RS1001110356 (6:110395652 G>T), RS1001117921 (6:110403101 T>C)

Disease associations

OMIM: gene MIM:124450 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

20 associations (top):

StudyTraitp-value
GCST003155_53Systemic lupus erythematosus1.000000e-07
GCST003518_86Daytime sleep phenotypes3.000000e-07
GCST004599_43Mean platelet volume8.000000e-28
GCST004603_29Platelet count2.000000e-14
GCST004616_182Platelet distribution width4.000000e-53
GCST004616_25Platelet distribution width2.000000e-55
GCST006879_15Blood metabolite levels6.000000e-25
GCST006879_16Blood metabolite levels5.000000e-08
GCST006879_17Blood metabolite levels2.000000e-26
GCST006879_23Blood metabolite levels7.000000e-31
GCST006879_24Blood metabolite levels3.000000e-25
GCST006879_3Blood metabolite levels8.000000e-29
GCST006879_4Blood metabolite levels7.000000e-37
GCST90002390_445Mean corpuscular hemoglobin7.000000e-13
GCST90002392_691Mean corpuscular volume1.000000e-17
GCST90002395_483Mean platelet volume2.000000e-12
GCST90002395_484Mean platelet volume8.000000e-13
GCST90002401_533Platelet distribution width2.000000e-26
GCST90002401_534Platelet distribution width1.000000e-117
GCST90002402_702Platelet count7.000000e-17

EFO canonical traits (4, from GWAS)

EFO IDTrait name
EFO:0007828daytime rest measurement
EFO:0004309platelet count
EFO:0007984platelet component distribution width
EFO:0004527mean corpuscular hemoglobin

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5887 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

21 measured of 22 human assays (23 total across all organisms); most potent 21 below. Values come from heterogeneous assays and are not directly comparable.

LigandMeasureValue
3-hydroxyquinolin-2(1H)-one, 3IC503 nM
naphthyridinone analog., 27IC503 nM
3-hydroxyquinolin-2(1H)-one, 10IC504 nM
3-hydroxyquinolin-2(1H)-one, 26IC505 nM
3-hydroxyquinolin-2(1H)-one, 6IC508 nM
3-hydroxyquinolin-2(1H)-one, 15IC508 nM
naphthyridinone analog.,18IC508 nM
4H-furo[3,2-b]pyrrole-5-carboxylic acidIC509 nM
3-hydroxyquinolin-2(1H)-one, 5IC509 nM
3-hydroxyquinolin-2(1H)-one, 4IC5010 nM
3-hydroxyquinolin-2(1H)-one, 14IC5016 nM
naphthyridinone analog.,19IC5032 nM
3-hydroxyquinolin-2(1H)-one, 7IC5033 nM
3-hydroxyquinolin-2(1H)-one, 11IC5038 nM
3-hydroxyquinolin-2(1H)-one, 8IC50100 nM
naphthyridinone analog.,21IC50128 nM
3-hydroxyquinolin-2(1H)-one, 9IC50155 nM
3-hydroxyquinolin-2(1H)-one, 12IC50197 nM
naphthyridinone analog.,20IC50784 nM
3-hydroxyquinolin-2(1H)-one, 17IC5014400 nM
3-hydroxyquinolin-2(1H)-one, 23IC5017300 nM

ChEMBL bioactivities

3 potent at pChembl≥5 of 14 total, top 3 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChemblTypeValueUnitMolecule
6.07IC50855nMCHEMBL146227
5.42Ki3800nMCHEMBL1491941
5.33IC504620nMCHEMBL494235

PubChem BioAssay actives

5 with measured affinity, of 143 total; 3 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

CompoundAssayTypeValueUnit
3-hydroxy-1H-quinolin-2-one1799106: DAAO in Vitro Activity Assay from Article 10.1021/jm900128w: “Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.”ic500.8550uM
5-aminopyridine-3-carboxylic acid1247846: Binding affinity to human recombinant DDOki3.8000uM
8-fluoro-3-hydroxy-1H-quinolin-2-one1799106: DAAO in Vitro Activity Assay from Article 10.1021/jm900128w: “Discovery, SAR, and pharmacokinetics of a novel 3-hydroxyquinolin-2(1H)-one series of potent D-amino acid oxidase (DAAO) inhibitors.”ic504.6200uM

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

ChemicalActions (top 5)PubMed papers
aristolochic acid Iincreases expression1
dicrotophosdecreases expression1
propionaldehydedecreases expression1
pirinixic acidaffects binding, increases activity, increases expression1
terbufosincreases methylation1
nickel sulfateincreases expression1
perfluorooctane sulfonic acidincreases expression1
CGP 52608affects binding, increases reaction1
Acetaminophendecreases expression1
Benzo(a)pyreneincreases methylation1
Fonofosincreases methylation1
Ethyl Methanesulfonateincreases expression1
Formaldehydeincreases expression1
Methyl Methanesulfonateincreases expression1
Parathionincreases methylation1
Tobacco Smoke Pollutiondecreases expression1
Isotretinoindecreases expression1
Okadaic Aciddecreases expression1
Copper Sulfatedecreases expression1
S-Nitrosoglutathioneincreases expression1

ChEMBL screening assays

13 unique, capped per target: 13 binding

Representative assays (with source publication via chembl_document):

Assay IDTypeDescriptionSource paper
CHEMBL2327933BindingInhibition of human recombinant N-terminal His-tagged DDO expressed in Escherichia coli BL21(DE3) using D-aspartate as substrate by colorimetric assayIdentification of novel D-amino acid oxidase inhibitors by in silico screening and their functional characterization in vitro. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 78

This page pulls from 78 datasets indexed by BioBTree:

alphafoldalphamissenseantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticsccdscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetciviccivic_evidenceclingen_dosageclingen_gene_validityclinical_trialsclinvarcollectrictd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityexonfantom5_genefantom5_promotergenccgenerifgogoparentgtopdbgwasgwas_studyhgnchpointactinterprointogenjasparmeshmimmirdbmondomsigdborphanetorthologparalogpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assaypubmedreactomereactomeparentrefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorspliceaistring_interactiontranscriptufeatureuniprot